News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Lonza Group Full Year Results 2008
February 4, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Record EBIT of CHF 441 million (+8%; +12% on a comparable basis) Net income growth of 39% further strengthening the investment-grade balance sheet and supporting the ability to generate further sustainable growth
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
Lonza
MORE ON THIS TOPIC
FDA
Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay
May 13, 2026
·
1 min read
·
Heather McKenzie
Layoff Tracker
BioMarin trims Amicus headcount after acquisition
May 13, 2026
·
51 min read
·
BioSpace Editorial Staff
Venture capital
AI-fueled Isomorphic bags $2.1B, the second largest biotech round ever
May 13, 2026
·
2 min read
·
Tristan Manalac
Business
BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal
May 12, 2026
·
2 min read
·
Tristan Manalac